insights_auto
Why is DMN down 2,31%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,068 €
arrow_downward
-2,31%(-0,0016) 1D
10 նոյ, 20:15:15 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,08 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
147,08 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
Central Oregon Daily
·
26 րոպե առաջ
Wall St retreats as hot inflation data, Fed comments fuel rate worries
Yahoo Finance
·
19 րոպե առաջ
3 Ways to Protect Your Portfolio After the S&P 500's Worst Day Since April 2025
Benzinga
·
14 րոպե առաջ
Earnings Beats Ignored Like the Dot-Com Bust, BofA Says - State Street SPDR S&P 500 ETF Trust (ARCA:SPY)
The Motley Fool
·
2 ժամ առաջ
Is the S&P 500 Heading for a Correction?
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB